Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Study MEA117106: Mepolizumab vs. Placebo as add-on Treatment for Frequently Exacerbating COPD Patients

Next Previous
Trial Profile

Study MEA117106: Mepolizumab vs. Placebo as add-on Treatment for Frequently Exacerbating COPD Patients

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 27 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Mepolizumab (Primary)
  • Indications Chronic obstructive pulmonary disease
  • Focus Registrational; Therapeutic Use
  • Acronyms METREX
  • Sponsors GlaxoSmithKline; GSK

Most Recent Events

  • 22 May 2025 According to a GlaxoSmithKline media release, based on data from MATINEE and METREX phase III trials, the US Food and Drug Administration (FDA) has approved Nucala (mepolizumab) as an add-on maintenance treatment for adult patients with inadequately controlled COPD and an eosinophilic phenotype.
  • 05 Jul 2019 Results (n=1136) of post-hoc analysis of intention-to-treat population from two studies (METREX and METREO) assessing genetic association of mepolizumab in chronic obstructive pulmonary disease, published in the Respiratory Medicine.
  • 19 Sep 2018 Results from METREX and METREO studies, presented at the 28th Annual Congress of the European Respiratory Society.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top